You are here:

brodalumab (Kyntheum)

Advice

following a full submission:

brodalumab (Kyntheum®) is not recommended for use within NHS Scotland.

Indication under review: for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy.

brodalumab was superior to placebo and to an alternative interleukin inhibitor at improving symptoms in adults with moderate to severe plaque psoriasis.

The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC.

Drug Details

Drug Name: brodalumab (Kyntheum)
SMC Drug ID: 1283/17
Manufacturer: LEO Pharmaceuticals
Indication: For the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy.
BNF Category:
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 11 December 2017

Back